In the concentrations used in our study, AML acts as a long-lasting Ca2+ channel blocker (Figure S12, Supplementary Materials), but apparently locates not exclusively to its target, CaV1.2. This evidence concerns the gene CACNA1C and acute myeloid leukemia.